Avoiding Anticoagulation After IntraCerebral Haemorrhage
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT03243175
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT03243175 -
2017-004371-31
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT03243175. Randomized; single masking; primary purpose prevention. Start 2019-01-17 (actual); primary completion 2029-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Avoiding Anticoagulation After IntraCerebral Haemorrhage
- Acronym
- A3ICH
- Condition
- Intracerebral Hemorrhage
- Condition
- Atrial Fibrillation
- Condition
- Microhaemorrhage
- Intervention (Drug)
- Apixaban 5 MG
- Intervention (Device)
- left atrial appendage closure
- Lead sponsor
- University Hospital, Lille
- Collaborator
- Ministry of Health, France
- Collaborator
- Institut National de la Santé Et de la Recherche Médicale, France
Record details
- Record id
cardio:ct-nct03243175- Content hash
d99eda65a8494ac01b7baa1c1478348c9b717839d3057ec6f159951a60f67520